{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:33Z","timestamp":1786207353067,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1245\/s10434-026-19949-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:52:15Z","timestamp":1781121135000},"page":"8335-8347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology"],"prefix":"10.1245","volume":"33","author":[{"given":"Cary Jo R.","family":"Schlick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan L.","family":"Dikken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina T.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela","family":"Capanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumika","family":"Jadeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray F.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian E.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Ilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Y.","family":"Janjigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Coit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"1","key":"19949_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"19949_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, et al. Gastric Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"19949_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00423-011-0805-8","volume":"397","author":"S Blank","year":"2012","unstructured":"Blank S, Bl\u00e4ker H, Schaible A, Lordick F, Grenacher L, Buechler M, Ott K. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbeck\u2019s Arch Surg. 2012;397(1):45\u201355.","journal-title":"Langenbeck\u2019s Arch Surg."},{"issue":"3","key":"19949_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10120-016-0637-x","volume":"20","author":"E Bando","year":"2017","unstructured":"Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Terashima M. Impact of clinical tumor\u2013node\u2013metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer. 2017;20(3):448\u201356.","journal-title":"Gastric Cancer."},{"issue":"1","key":"19949_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/curroncol28010017","volume":"28","author":"KA Stahl","year":"2020","unstructured":"Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric cancer treatments and survival trends in the United States. Curr Oncol. 2020;28(1):138\u201351.","journal-title":"Curr Oncol."},{"issue":"10294","key":"19949_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet."},{"issue":"1","key":"19949_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjsurg.2005.10.015","volume":"191","author":"AI Sarela","year":"2006","unstructured":"Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191(1):134\u20138.","journal-title":"Am J Surg."},{"issue":"12","key":"19949_CR8","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1245\/s10434-010-1183-0","volume":"17","author":"JJ Mezhir","year":"2010","unstructured":"Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome in 291 patients. Ann Surg Oncol. 2010;17(12):3173\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"19949_CR9","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1245\/s10434-008-0055-3","volume":"15","author":"B Badgwell","year":"2008","unstructured":"Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA, Lupo PJ, Pisters PW, Feig B, Mansfield P. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008;15(10):2684\u201391.","journal-title":"Ann Surg Oncol"},{"key":"19949_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"M-Z Qiu","year":"2024","unstructured":"Qiu M-Z, Oh D-Y, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee K-W, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu R-H. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomized, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"issue":"3","key":"19949_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1091-255X(98)80019-X","volume":"2","author":"U Ribeiro","year":"1998","unstructured":"Ribeiro U, Gama-Rodrigues JJ, Safatle-Ribeiro AV, Bitelman B, Ibbrahim RE, Feweira MB, Laudanna AA, Pinotti HW. Prognostic significance of intraperitoneal free cancer cells obtained by laparoscopic peritoneal lavage in patients with gastric cancer. J Gastrointest Surg. 1998;2(3):244\u20139.","journal-title":"J Gastrointest Surg."},{"issue":"5","key":"19949_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/bjs.1800830526","volume":"83","author":"JJ Bonenkamp","year":"1996","unstructured":"Bonenkamp JJ, Songun I, Hermans J, Van Velde CD. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg. 1996;83(5):672\u20134.","journal-title":"Br J Surg."},{"issue":"5","key":"19949_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1245\/ASO.2005.03.065","volume":"12","author":"D Bentrem","year":"2005","unstructured":"Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347\u201353.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"19949_CR14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10147-021-01873-4","volume":"26","author":"S Endo","year":"2021","unstructured":"Endo S, Nishikawa K, Ikenaga M, Fujitani K, Kawada J, Yamatsuji T, Kubota H, Higashida M, Fujiwara Y, Ueno T. Prognostic factors for cytology-positive gastric cancer: a multicenter retrospective analysis. Int J Clin Oncol. 2021;26(5):858\u201366.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"19949_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12957-021-02351-x","volume":"19","author":"M Valletti","year":"2021","unstructured":"Valletti M, Eshmuminov D, Gnecco N, Gutschow CA, Schneider PM, Lehmann K. Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. World J Surg Oncol. 2021;19(1):245.","journal-title":"World J Surg Oncol"},{"issue":"18","key":"19949_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJ, Hulshof MC, van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS Trial. J Clin Oncol. 2021;39(18):1995\u20132004.","journal-title":"J Clin Oncol"},{"issue":"1","key":"19949_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"10184","key":"19949_CR18","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"3","key":"19949_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318.","journal-title":"Lancet Oncol"},{"issue":"12","key":"19949_CR20","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1245\/s10434-009-0706-z","volume":"16","author":"H Okabe","year":"2009","unstructured":"Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16(12):3227\u201336.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"19949_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, Lerchenmueller C, Reim D, Wahba R, Angele M, Heeg S. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146\u201356.","journal-title":"J Clin Oncol"},{"issue":"19","key":"19949_CR22","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"key":"19949_CR23","unstructured":"Yan C (2024) Intraperitoneal paclitaxel combination regimen improves overall survival in advanced gastric cancer. ASCO GI"},{"issue":"Suppl 1","key":"19949_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10120-011-0071-z","volume":"15","author":"PA Leake","year":"2012","unstructured":"Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Rowsell C, Coburn NG. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):27\u201337.","journal-title":"Gastric Cancer."},{"issue":"24","key":"19949_CR25","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41388-024-03034-z","volume":"43","author":"K van de Sluis","year":"2024","unstructured":"van de Sluis K, et al. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid. Oncogene. 2024;43(24):1877\u201382.","journal-title":"Oncogene"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19949-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:48:42Z","timestamp":1786204122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19949-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19949"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19949-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.S. received speaking honoraria from Astra Zeneca. S.M. received honoraria from Amgen, Pinetree Therapeutics, Elevation Oncology, Purple Oncology, Bolt Therapeutics, Everest Oncology, and Daiichi Sankyo; has financial interest in OneCellDx; received research funding from Conquer Cancer Foundation; and received research support from AstraZeneca and Paige.AI. Y.J. received research funding from Astellas, AstraZeneca, Arcus Biosciences, Bayer, Bristol-Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly, Fred\u2019s Team, Genentech\/Roche, Inspirna, Merck, NCI, Stand Up 2 Cancer, and Transcenta; received advisory board\/consulting fees from Abbvie, Alphasights, Amerisource Bergen, Ask-Gene Pharma, Inc., Arcus Biosciences, Astellas, Astra Zeneca, Basilea Pharmaceutica, Bayer, BeOne, Boehringer Ingelheim, Bristol-Myers Squibb, Clinical Care Options, Daiichi-Sankyo, Debbie\u2019s Dream Foundation, eChina Health, Ed Med Resources (OncInfo), Eisai, Eli Lilly, Geneos Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant Health, Inc., H.C. Wainwright & Co., Health Advances, HMP Global, I3Health, Imedex, Imugene, Inspirna, Lynx Health, Mashup Media LLC, Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, Michael J. Hennessy Associates, Oncology News, OncoDaily, Paradigm Medical Communications, PeerMD, PeerView Institute, Pfizer, Physician\u2019s Education Resource, LLC, Research to Practice, Sanofi Genzyme, Seagen, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co., Ltd, Talem Health, TotalCME, WebMD, and Zymeworks Inc; and has stock options in OncoDaily.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Ethics"}}]}}